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ABSTRACT 
Neurons affected in a wide variety of unrelated adult-onset neurodegenerative diseases (AONDs) typically 
exhibit a “dying back” pattern of degeneration, which is characterized by early deficits in synaptic function and 
neuritic pathology long before neuronal cell death. Consistent with this observation, multiple unrelated AONDs 
including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and several motor neuron diseases 
feature early alterations in kinase-based signaling pathways associated with deficits in axonal transport (AT), a 
complex cellular process involving multiple intracellular trafficking events powered by microtubule-based motor 
proteins. These pathogenic events have important therapeutic implications, suggesting that a focus on 
preservation of neuronal connections may be more effective to treat AONDs than addressing neuronal cell 
death. While the molecular mechanisms underlying AT abnormalities in AONDs are still being analyzed, 
evidence has accumulated linking those to a well-established pathological hallmark of multiple AONDs: altered 
patterns of neuronal protein phosphorylation. Here, we present a short overview on the biochemical 
heterogeneity of major motor proteins for AT, their regulation by protein kinases, and evidence revealing cell 
type-specific AT specializations. When considered together, these findings may help explain how independent 
pathogenic pathways can affect AT differentially in the context of each AOND.  
 
  
1. INTRODUCTION 
  
Adult-onset neurodegenerative diseases (AONDs) represent some of the most difficult human health 
challenges remaining. AONDs comprise a heterogeneous group of neurological disorders including 
Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD), as well as motor neuron 
diseases such as amyotrophic lateral sclerosis (ALS) and hereditary spastic paraplegias (HSPs). Despite their 
different etiology, all AONDs feature a sustained decline in the functionality of selected neuronal populations, 
with the identity of such populations playing a major role on the unique set of clinical symptoms that 
characterize each disease. As a major risk factor for most AONDs is aging, the longer lifespans in the modern 
era lead to an increased number of people affected by these diseases, making our need to understand 
pathogenic mechanisms imperative (Mattson and Magnus, 2006).  
 Novel insights on AONDs pathogenesis arrived with the identification of gene mutations associated with 
familial forms of AONDs (Jagmag et al., 2015; McGoldrick et al., 2013; Pouladi et al., 2013; Ribeiro et al., 
2013; Wong et al., 1998). While clearly major breakthroughs, these genetic studies left investigators in the 
neurodegenerative disease research community with more questions than answers. More often than not, 
specific biological functions for most AOND-associated gene products remain unknown and for those gene 
products with an established function (i.e.; conversion of free superoxide radicals to peroxide by superoxide 
dismutase 1; SOD1), pathogenic mutations were found that did not affect such function (Pardo et al., 1995). 
Remarkably, many AOND-associated mutant gene products are widely expressed, yet only certain neuronal 
populations exhibit pathology while non-neuronal cells and many other neuronal cell types are spared. For 
example amyloid precursor protein (APP) and the microtubule-associated protein tau are abundant proteins 
found in all neurons and both are closely associated with pathology in AD (Rosenberg et al., 2016). However, 
AD-related mutations in APP preferentially affect neurons in the hippocampus and frontal cortex, while sparing 
neurons in other brain regions such as motor cortex and cerebellum (Gonzalez-Dominguez et al., 2014). On 
the other hand, mutations in tau protein are not implicated in AD, but are instead associated with a variety of 
different tauopathies and some forms of frontotemporal dementia; corticobasal degeneration; progressive 
supranuclear palsy; and Pick’s disease among others) that exhibit degeneration in different neuronal 
populations (Gonzalez-Dominguez et al., 2014). Alterations in the pattern of tau phosphorylation have also 
been reported in other unrelated AONDs, such as HD (Gratuze et al., 2016). However, the large number of 
phosphorylation sites in tau make it difficult to determine their specific contribution to pathogenesis in those 
diseases (Zerr and Bahr, 2016). Similarly, mutations in the highly abundant and ubiquitously expressed SOD1 
cause familial forms of ALS, which primarily features dying back degeneration of upper and lower motor 
neurons (Ozdinler et al., 2011), leaving other neuronal populations largely spared (Fischer et al., 2004; Wong 
et al., 2002). Complicating matters further, idiopathic AONDs in patients with no family history cannot easily be 
distinguished from familial forms and mutations in multiple, structurally unrelated gene products may result in 
phenotypically indistinguishable forms of AONDs (Fink, 2013; Wong et al., 2002). 
 More revealing was the observation that most pathogenic gene mutations in familial AONDs are inherited 
in an autosomal dominant manner, and knocking out these genes failed to replicate AOND symptoms [see for 
example (Reaume et al., 1996; Zeitlin et al., 1995)]. Collectively, observations derived from genetic findings 
appear consistent with a scenario where multiple independent pathogenic pathways, typically involving a toxic 
gain of function, affect cellular processes critical for neuronal function. Identification of these processes and the 
cellular factors contributing to differential vulnerability of specific neuronal populations in each AOND will prove 
invaluable for the development of effective therapeutic strategies. As discussed below, an analysis of early 
pathogenic events common to AONDs provide hints on the identity of such processes. 
 
Neurons affected in AONDs undergo a progressive loss of synaptic and neuritic connectivity. 
 For decades, the significant neuronal loss observed in post-mortem brains of patients affected by AONDs 
at advanced disease stages focused primary research efforts on understanding of cell death-related 
mechanisms (Martin, 2001). To that end, identification of mutant genes associated with familial forms of 
AONDs allowed the development of animal models, which recapitulated major clinical hallmarks observed in 
human AONDs. These models provided researchers with an unprecedented opportunity to reveal early, 
presymptomatic pathogenic events in the context of specific AONDs. Remarkably, analysis of multiple 
unrelated AOND models revealed consistent alterations in neuronal connectivity that were concurrent or even 
preceded the manifestation of clinical symptoms (Adalbert and Coleman, 2013; Vickers et al., 2009). 
Phenotypically, such deficits manifested as behavioral and motor abnormalities in the absence of significant 
neuronal cell death, suggesting that clinical symptoms of AONDs result from neuronal dysfunction or 
disconnection, rather than loss of neurons (Brady and Morfini, 2010; Coleman, 2011). A significant body of 
pathological evidence provided a cellular basis for these functional abnormalities, documenting synaptic 
dysfunction (Henstridge et al., 2016; Wishart et al., 2006) and neuritic atrophy (Bellucci et al., 2016; Fischer 
and Glass, 2007; Gatto et al., 2015; Kanaan et al., 2013) in animal models of multiple unrelated AONDs. In 
some familial forms of AONDs, brain imaging-based studies highlighted the relevance of these findings, 
documenting microstructural alterations in white matter, axon-rich brain areas of living presymptomatic patients 
(Poudel et al., 2014; Rosas et al., 2010).  
 Collectively, the available data indicates that neurons affected in AONDs undergo a gradual loss of 
synaptic and neuritic connectivity, early pathogenic events that appear responsible for the disease-specific 
neurological symptoms. Accordingly, therapeutic strategies that successfully prevented neuronal cell death in 
various animal models of AONDs failed to prevent the progression of clinical symptoms (Djaldetti et al., 2003; 
Gould et al., 2006; Waldmeier et al., 2006) and targeting prevention of neuronal cell death in humans have 
been similarly ineffective (Waldmeier et al., 2006). Instead, the degeneration pattern of neurons affected in 
AONDs suggests that maintenance of neuronal connectivity may be a better target for therapeutic intervention 
than prevention of cell death (Cheng et al., 2010; Lingor et al., 2012). However, such strategies require 
knowledge of mechanisms underlying loss of connectivity in the context of each AOND (Conforti et al., 2007; 
Gerdts et al., 2016; Luo and O'Leary, 2005). Unfortunately, the study of mechanisms has been hampered in 
part due to the scarcity of experimental systems designed to study axon and synapse-specific molecular 
events in isolation (Grant et al., 2006; Leopold et al., 1994; Llinas et al., 1992). 
 
Pathological hallmarks common to unrelated AONDs: commonalities amid diversity  
 As a group, AONDs share a number of common features (see Table 1). A major one includes the 
increased vulnerability of certain populations of projection neurons, which typically extend axons to 
anatomically distant targets. In contrast, interneurons that bear short axons usually confined to the boundaries 
of specific brain structures are commomly spared or affected very late in the course of AONDs. Along with 
other cellular factors, such morphological differences appear to contribute to the differential vulnerability of 
specific neuronal populations observed in each disease (Han et al., 2010; Mattson and Magnus, 2006; Parent 
and Parent, 2006; Prensa et al., 2009). 
 At the cellular level, early pathological events common to neurons affected in all AONDs include synaptic 
dysfunction and neurite atrophy, characteristic features of neurons undergoing dying-back degeneration 
(Arendt, 2009; Fischer et al., 2004; Li and Conforti, 2013; Morfini et al., 2009a; Wishart et al., 2006). At the 
molecular level, another notable hallmark common to all AONDs is evidence of alterations in kinase-based 
signaling pathways, reflected by changes in the phosphorylation pattern of various neuronal protein substrates 
(Hu and Krieger, 2002; Krieger et al., 2003; Wagey and Krieger, 1998). Finally, data has accumulated 
indicating that many AONDs exhibit early alterations in axonal transport (AT), a cellular process critical for 
appropriate maintenance of synaptic function and neuritic connectivity (Morfini et al., 2009a; Roy et al., 2005). 
Significantly, many of the kinase pathways associated with AONDs also affect AT (Morfini et al., 2009a). 
 While the specifics of each AOND are distinctive (i.e. identity of affected neurons, which proteins are 
differentially phosphorylated, and kinase pathways involved), patterns have begun to emerge that connect 
these common hallmarks above, revealing disease-specific stories with a common mechanistic theme: 
aberrant activation of selected kinase pathways in each AOND promote a variety of AT alterations, which in 
turn promote synaptic dysfunction and neuritic pathology in affected neurons (Kanaan et al., 2013; Morfini et al., 
2009a). Given the unique cellular topography of each AOND, such a mechanistic view would predict that cell 
type-specific features may render selected neuronal populations increasingly vulnerable to alterations in a 
given kinase pathway (Han et al., 2010; Perez-Navarro et al., 2006). Consistent with this notion, some drug 
treatments produce differential phosphorylation patterns in different neuronal cell types (Bateup et al., 2008; 
Bertran-Gonzalez et al., 2008). Also, many protein kinases and phosphatases display a unique tissue 
ditribution pattern (Boulanger et al., 1995) and even ubiquitously expressed protein kinases are expressed at 
different levels among different neuronal populations (Ackerley et al., 2004; Carboni et al., 1998).  
 
Altered kinase-based signaling in AONDs. Under normal conditions, phosphorylation events are carefully 
regulated both spatially and temporally within neurons, but these functions are often disrupted in disease 
state(s) (Walaas and Greengard, 1991). Aberrant phosphorylation of neuronal proteins represents a consistent 
feature of  AONDs that reflects abnormal activation of one or more kinase-based signaling pathways (Tenreiro 
et al., 2014). Classic examples of aberrantly phosphorylated proteins are tau and neurofilaments, major 
phosphoprotein components of the axonal cytoskeleton (Grant and Pant, 2000; Holmgren et al., 2012; Khan 
and Bloom, 2016; Stoothoff and Johnson, 2005).  
 In AD, for example, a variety of kinases have been associated with aberrant tau phosphorylation 
including MAP kinases, cyclin-dependent protein kinase 5 (cdk5), casein kinase 2 (CK2), casein kinase I (CK1) 
and MAP/microtubule affinity-regulating kinases (MARKs), but the kinase activity most consistently associated 
with tau phosphorylation in AD is glycogen synthase kinase 3 (GSK3) (Wang et al., 2007).  Increased 
phosphorylation of tau is also seen in a variety of other neurodegenerative diseases including PD (Kawakami 
and Ichikawa, 2015), HD (Gratuze et al., 2015), ALS (Strong et al., 2006), FTDP17 and various tauopathies 
(Spillantini and Goedert, 2013; Stoothoff and Johnson, 2005). Significantly, recent studies indicate that GSK3β 
may be activated by pathogenic forms of tau and amyloid beta (Aβ) (Hernandez et al., 2010; Kanaan et al., 
2011; Pigino et al., 2009). Specifically, pathogenic forms of tau were shown to activate a pathway leading to 
GSK3 activation within both axons (Kanaan et al., 2011; Lapointe et al., 2009) and synapses (Moreno et al., 
2016). In addition, oligomeric forms of amyloid beta (Aβ) were found to activate CK2 within these 
compartments (Moreno et al., 2009; Pigino et al., 2009). Given the complexity and crosstalk among kinase 
pathways in both normal and pathological states, multiple kinases are likely to promote aberrant patterns of tau 
phosphorylation in AD and other AONDs (Wang et al., 2007), making the identification of pathologically 
relevant ones a major challenge for investigators. 
 Another set of neuronal proteins commonly exhibiting altered phosphorylation in AONDs are the 
abundant neurofilament subunits NFH and NFM (Grant and Pant, 2000; Grant et al., 2006; Julien and 
Mushynski, 1998). Accumulation of highly phosphorylated neurofilaments in the initial segment of motor neuron 
axons is a major hallmark of ALS (Ackerley et al., 2004; Xiao et al., 2006), and many other unrelated AONDs 
display changes in neurofilament phosphorylation (Holmgren et al., 2012). Findings of abnormal tau and 
neurofilament phosphorylation in multiple unrelated AONDs likely reflects the large number and variety of 
consensus phosphorylation sites in these proteins (Veeranna et al., 2008), which may or may not affect their 
functionality. Regardless, their abundance and degree of phosphorylation in neurons, combined with the 
availability of antibodies against many of their phospho-specific epitopes makes these proteins a uniquely 
sensitive reporter for alterations in neuronal kinase activity.   
 While many studies document aberrant phosphorylation of tau or neurofilaments in AONDs, less 
consideration has been given to detailing other consequences of altered kinase signaling. Indeed, most 
kinases have multiple cellular substrates, and a wide variety of cellular processes undergo kinase-based 
regulation including gene transcription and translation [see for examples (Gao and Roux, 2015; Thapar and 
Denmon, 2013; Whitmarsh, 2007)], channel functionality (Chahine and O'Leary, 2014), cytoskeleton 
organization (Rudrabhatla, 2014), and intracellular trafficking of proteins and cellular organelles (Gibbs et al., 
2015; Morfini et al., 2009a). As discussed below, a cellular process affected by deregulated kinases with 
particular relevance for AOND pathogenesis may be AT. This is because the size and complex morphology of 
neurons make them uniquely vulnerable to changes in intracellular trafficking and, as discussed below, even 
minor disruptions in AT result in dying-back degeneration of neurons.  
 
Axonal transport (AT): A complex set of intracellular trafficking events critical for the maintenance of 
neuritic connectivity. Major cellular processes involved in the survival and functionality of most cell types 
depend upon microtubule-based intracellular trafficking mechanisms. However, appropriate functionality of 
these mechanisms is particularly important in neurons, because their neuritic processes (i.e.; dendrites and 
axons), together comprise the overwhelming bulk of the total cell volume, yet the cellular machinery needed for 
the synthesis and packaging of proteins and lipids is mainly restricted to the somatodendritic compartment 
(Morfini et al., 2012; Morfini et al., 2001; Pigino et al., 2012). In addition, the remarkable biochemical and 
functional heterogeneity observed in specific neuritic subcompartments (i.e, pre- and post-synapses, nodes of 
ranvier, axon hillock, etc) makes the trafficking of molecular components within neuritic processes a major 
requirement for neuronal function and survival (Britt et al., 2016).  
 The term “axonal transport” (AT) refers to a wide variety of intracellular trafficking events, all required for 
appropriate maintenance of synaptic function and neuritic connectivity [reviewed in (Black, 2016; Britt et al., 
2016; Maeder et al., 2014; Morfini et al., 2012)]. Such events include the regulated delivery of membrane-
bounded organelles (MBOs) synthesized and packaged in the neuronal soma to pre- and post-synaptic 
compartments, as well as the removal and degradation of old materials. AT also mediates the delivery and 
turnover of non-synaptic membrane components, metabolic and cytoskeletal elements needed to generate and 
maintain the structural and biochemical heterogeneity that characterizes axonal and dendritic subdomains. 
Finally, AT carries neurotrophic signals that provide neuronal somata with information from distant target cells, 
including the integrity of synaptic connections. Accordingly, AT can be regarded as a major cellular process 
underlying the generation and maintenance of neuronal architecture and connectivity throughout the long 
lifetime of neurons (van den Berg and Hoogenraad, 2012). A brief overview of the heterogeneity of the major 
AT motor proteins reponsible for the execution of AT provides a glimpse on the remarkable complexity of this 
process. 
 
Conventional kinesin and cytoplasmic dynein are major microtubule-based motor proteins powering 
axonal transport of membrane-bounded organelles. Microtubule-based molecular motor proteins recognize 
the intrinsic polarity of microtubules, selectively moving towards their plus or their minus ends (Falnikar and 
Baas, 2009). Based on this property, the organization of microtubules within neurites provides a basis for the 
vectorial transport of MBO cargoes in the retrograde (from the cell periphery towards the cell soma) and the 
anterograde (away from the neuronal soma) directions (Black, 2016; Morfini et al., 2012). Retrograde AT 
involves the translocation of signaling complexes and MBOs carrying components targeted for degradation 
from synaptic terminals and distal axons to the neuronal cell body by the multisubunit motor protein complex 
cytoplasmic dynein (CDyn) (Delcroix et al., 2004; Harrington and Ginty, 2013; Ito and Enomoto, 2016). On the 
other hand, anterograde AT is powered by members of the kinesin superfamily of motor proteins (KIFs) (Brady, 
1995; Brady and Sperry, 1995; Hirokawa et al., 2010). 
 Based on phylogenetic analysis and sequence homology, KIF superfamily members have been classified 
into 15 KIF subfamilies, termed kinesin-1 to kinesin-14B (Lawrence et al., 2004). From all these, conventional 
kinesin represents the most abundant class of KIF superfamily members in the mature nervous system (Brady, 
1995; Wagner et al., 1989), being involved in anterograde AT of a wide variety of MBOs including synaptic 
vesicle precursors, axolemmal proteins, and mitochondria, among others (Elluru et al., 1995; Feiguin et al., 
1994; Leopold et al., 1992; Tanaka et al., 1998). As a holoenzyme, conventional kinesin exists as a rod-
shaped heterotetramer composed of two heavy chain (KIF5s, kinesin-1s) and two light chain (KLCs) subunits 
(Deboer et al., 2008) (Fig. 1).  
 Kinesin-1s are responsible for the mechanochemical properties of conventional kinesin, featuring both 
microtubule-binding and ATPase domains. In mammals, the kinesin-1 subfamily comprises three genes, which 
encode KIF5A KIF5B and KIF5C, (Hirokawa et al., 2010) (Fig. 1). KIF5A is thought to be primarily neuronal, 
while KIF5B and KIF5C are ubiquitously expressed [KIF5C is relatively enriched in many neurons (Kanai et al., 
2000)]. Each kinesin-1 appears to fulfill a unique set of specialized functions, as suggested by their differential 
tissue distribution profiles and the diverse set of phenotypes associated with their deletion (Nakajima et al., 
2012; Tanaka et al., 1998; Xia et al., 2003) (see also Fig. 2). However, all kinesin-1s feature a highly 
conserved domain organization [reviewed in (Jeppesen and Hoerber, 2012)]. A head motor region, located at 
the amino-terminus, comprises the microtubule binding and ATPase hydrolysis domains responsible for the 
mechanochemical properties of the conventional klnesin holoenzyme. Towards the carboxy terminus, a neck-
linker follows, which plays an important role in processive movement and step coordination. The head and 
neck-linker domains are followed by a long stalk region containing a hinge and two coiled-coil domains with the 
first one responsible for dimerization of kinesin-1 subunits and the second involved in mediating interactions 
with KLC subunits. Finally, the extreme C-terminal tail of kinesin-1 comprises a small globular domain featuring 
the most divergent sequence stretches among kinesin-1 subfamily members (Jeppesen and Hoerber, 2012).  
 More closely associated to the transported MBO cargo, KLC subunits localize to the end of the stalk 
domain of conventional kinesin (Fig.1). Two KLC genes are expressed in mammalian nervous tissue (KLC1 
and KLC2) and KLC1 undergoes alternative splicing in its extreme carboxy-terminal sequence (Cyr et al., 
1991; Rahman et al., 1998). At their amino terminus, KLC subunits feature a coiled-coil region that mediates 
their heterodimerization with kinesin-1 subunits. In addition, the central region of KLCs features highly 
conserved DnaJ-like domains (Tsai et al., 2000) [also termed as Tandem Repeat domains (TRs) (Gindhart and 
Goldstein, 1996)]. In combination with kinesin-1 tail domains, TRs appear to mediate the tight interaction of 
conventional kinesin with MBO cargoes, and can recruit and activate the chaperone hsc70 for its detachment 
from MBO surfaces (Tsai et al., 2000).  
 Co-immunoprecipitation studies demonstrated that KIF5s and KLCs are exclusively organized as 
homodimers within the conventional kinesin holoenzyme (Deboer et al., 2008). Thus, at least six different 
variants of conventional kinesin can be defined by their subunit composition (Fig.1B), although many more 
variants are predicted based on alternative splicing of KLC1, so the ultimate number of unique conventional 
kinesin motors is uncertain (Morfini et al., 2016) (Fig. 1). The functional significance of these conventional 
kinesin variants has not been fully established, but cumulative experimental evidence suggests a role in both 
the binding to selected MBO cargoes (Dahlström et al., 1991; Deboer et al., 2008; Elluru et al., 1995; Szodorai 
et al., 2009) and their delivery to discrete neuritic subcompartments (Morfini et al., 2016). The diversity of 
kinesin-1 motors, coupled with the wide variety of cargos and subcellular compartments in neurons, suggest 
that multiple regulatory pathways must exist to control the delivery of specific cargoes to selected subcellular 
domains (Brady, 1995; Brady and Sperry, 1995; Morfini et al., 2016; Morfini et al., 2001).  
 Biochemical hegeterogeneity also exists for the multisubunit motor protein CDyn [reviewed in (Brill and 
Pfister, 2000; Vallee et al., 2004)] (Fig. 1). In mammals, the main core of this multisubunit motor protein 
complex features two dynein heavy chain (DHCs), and two intermediate chain (DIC) subunits (Brill and Pfister, 
2000). DHCs are responsible for the ATPase and microtuble-binding activities of CDyn, whereas DICs play a 
role on the binding of CDyn to a wide variety of MBO cargoes (Brill and Pfister, 2000; Vallee et al., 2004). In 
addition, CDyn can include various other subunits, including light intermediate chains (LICs) and various light 
chain subnits including LC8, roadblock and T-complex testis-specific protein 1 (TCTEX1) (Vallee et al., 2004), 
although the specific stoichiometries are unclear. There are also a variety of adaptors and modulators of CDyn 
such as the dynactin complex, Bic, as well as various proteins including Ndl and LIS (Hoogenraad and 
Akhmanova, 2016). Highlighting the biochemical heterogeneity of CDyn, the two DIC genes found in mammals 
(DIC1 and DIC2) undergo extensive tissue-specific alternative splicing (Susalka and Pfister, 2000). As 
observed for conventional kinesin, these findings imply the existence of a large number of CDyn subunit 
variants (Pfister, 2015). The biochemical heterogeneity of CDyn appears consistent with the wide diversity of 
cargoes transported by this motor protein, ranging from signalling endosomes (Ha et al., 2008) to microtubules 
(He et al., 2005; Hoogenraad and Akhmanova, 2016), and the diversity of kinase pathways that regulate the  
transport of neurotrophins and turnover of membrane components at synapses. Supporting this notion, a 
specific DIC1 splice variant (IC1B) was found to mediate retrograde AT of neurotrophin receptor-contaning 
endosomes in hippocampal neurons (Ha et al., 2008). 
 
One size does not fit all: cell type-specific specializations of axonal transport. The presence of isoforms 
and biochemically diverse subunit variants of molecular motors represent important parameters rarely 
addressed. The oversimplifications seen in simplified diagrams often obscure key aspects of fundamental 
mechanisms and lead to erroneous generalizations. In the context of AT, discussions and experiments 
addressing conventional kinesin or CDyn rarely consider subunit isotypes. Moreover, findings on the 
functionality and regulation of these molecular motors are often presented as relevant to all neuronal types. 
However, considerable diversity exists in the complement of microtubule-based motor subunits expressed in 
neurons, reflecting cell type-specific AT specializations (Fig. 2).  
 Initial hints of AT specializations stemmed from pulse-chase studies comparing the relative composition 
of proteins undergoing AT in optic and spinal axons  (Brady, 1988; Oblinger et al., 1987), and others 
addressing transport rates of specific conventional kinesin variants along the rat optic nerve (Elluru et al., 
1995). Studies on the composition of specific membrane-bounded cargo vesicles indicate selectivity as well. 
Thus, analysis of APP containing transport vesicles demonstrate an association with kinesin-1C-containing 
conventional kinesin motors (Szodorai et al., 2009), while studies on mitochondrial tranpsort have implicated 
kinesin-1B-based (Tanaka et al., 1998) and kinesin-1A is implicated in transport of GABA receptors (Nakajima 
et al., 2012). More recently, human pathologies associated with mutations in motor protein subunits extended 
these initial findings. For example, autosomal dominant loss-of-function mutations in KIF5A lead to a form of 
hereditary spastic paraplegia (SPG10-HSP) (Blair et al., 2006; Crimella et al., 2011; Reid et al., 2002; Tessa et 
al., 2008; Wang and Brown, 2010). Intriguingly, SPG10-HSP exhibits selective progressive dysfunction and 
dying-back degeneration of upper motor neurons,  even though most neurons express KIF5A (Fig. 2). While 
the specific MBO cargoes transported by kinesin-1A-containing variants of conventional kinesin have not been 
established, these observations suggest a unique dependence of upper motor neurons on the trafficking of 
cargoes powered by kinesin-1A-contaning variants of conventional kinesin. Alternatively, different kinesin-1 
isoforms may be subject to cell type-specific regulatory mechanisms (Morfini et al., 2016). Finally, other kinesin 
family members may play a greater role in some neuronal populations than others (Hirokawa et al., 2010), but 
this possibility is less well documented. 
 As observed for conventional kinesin, phenotypes elicited by mutations in specific CDyn subunits are 
variable, suggesting cell type-specific requirements in retrograde AT. For example, some mutations in the 
CDyn-associated protein p150glued primarily cause motor neuron disease (Puls et al., 2003; Puls et al., 2005), 
but other mutations in this protein are associated with Perry’s syndrome, which is characterized by 
degeneration of cortical and extrapyramidal neurons and lack motor neuron pathology (Eschbach and Dupuis, 
2011; Farrer et al., 2009). Similarly, mutations in DHC subunits differentially promote a wide variety of 
neurological phenotypes associated with degeneration of specific neuronal populations. Indeed, while some 
mutations are associated with a peripheral sensory neuropathy, others promote preferentially affect spinal 
motor neurons or striatal neuron pathology (Braunstein et al., 2010; Hafezparast et al., 2003) Since genetic 
deletion of DHCs precludes organism development, these observations suggest that either regulation or 
interaction of CDyn with specific cargos may be differentially compromised in a mutation-specific manner.  
 In sum, the discovery of neuropathologies associated with mutations in ubiquitously expressed motor 
protein subunits provides evidence for cell type-specific AT specializations, while also highlighting the unique 
reliance of selected populations of neurons to discrete alterations in AT. However, most AONDs have not been 
associated with mutations in motor protein subunits, suggesting that alternative molecular mechanisms 
underlie the deficits in AT documented in these diseases. Within this context, the identification of kinase-based 
pathways involved in the regulation of motor proteins provided novel insights on mechanisms linking various 
neuropathogenic proteins to deficits in AT (Morfini et al., 2009a). 
 
Phosphorylation-dependent regulation of motor proteins. To serve their function, MBOs transported by 
conventional kinesin need to be precisely delivered to spatially and functionally distinct subdomains within 
axons and dendrites (van den Berg and Hoogenraad, 2012). For example, in many CNS neurons, 
neurotransmitter-bearing synaptic vesicles are selectively delivered to hundreds or even thousands of 
presynaptic terminals en passant, whereas other vesicular MBOs containing ion channels need to be inserted 
at the plasma membrane within nodes of Ranvier. Such delivery of selected components at specialized neuritic 
subdomains long implied the existence of targeting mechanisms (Brady, 1995; Elluru et al., 1995; Morfini et al., 
2001). The realization that motor proteins are phosphorylated in vivo suggested that phosphorylation may 
represent a  molecular basis for targeted delivery in neurons (Donelan et al., 2002; Hollenbeck, 1990; 
Hollenbeck, 1993; Morfini et al., 2004; Morfini et al., 2002), but the challenge was to identify relevant kinases 
involved in the regulation of AT (Morfini et al., 2016; Morfini et al., 2001). 
 One preparation that provided key insights into candidate regulatory kinases for AT was the isolated 
squid axoplasm, a unique experimental model for the study of axon-specific molecular events, which earlier 
proved instrumental for the identification of molecular motors powering AT (Brady et al., 1982; Brady et al., 
1990; Kang et al., 2016; Song et al., 2016). Unlike other experimental systems where AT deficits may be an 
indirect effect of genes in gene expression, the effect of active protein kinases on AT could be directly 
evaluated in this ex vivo preparation, owing to the lack of plasma membrane. Consistent with the heterogeneity 
of axonal MBOs and the need for delivering those to specific axonal compartments, studies in isolated 
axoplasm identified multiple candidate regulatory kinases for AT [reviewed in (Morfini et al., 2001; Morfini et al., 
2009b)] (see Table 2). Further, specific phosphorylation events were identified, which differentially regulated 
the activities of conventional kinesin and CDyn (Gibbs et al., 2015; Martin, 2001; Morfini et al., 2009a). 
 Through direct or indirect phosphorylation at selected residues, specific kinases were found that 
modulated non-enzymatic activities of conventional kinesin. For example, GSK3 selectively inhibited 
conventional kinesin-based anterograde AT, but not CDyn-based retrograde AT in isolated axoplasm (Morfini 
et al., 2002). Biochemical experiments showed this inhibitory effect involved direct phosphorylation of KLC2 
subunits, an event associated with hsc70-mediated release of KLC2-containing conventional kinesin variants 
from their transported cargoes (Tsai et al., 2000) (Fig. 3). Extending these findings, other kinases were found 
to regulate AT indirectly by modulating localized GSK3 activation (Morfini et al., 2004; Ratner et al., 1998). 
Unlike most protein kinases, GSK3 activation requires dephosposphorylation of an inhibitory phosphorylation 
site (Grabinski and Kanaan, 2016). Interestingly, it was found that inhibition of the major protein kinase CDK5 
promotes activation of axonal protein phosphatase 1 (PP1), which in turn dephosphorylated and activated 
GSK3 (Morfini et al., 2004; Ratner et al., 1998). Additional protein phosphatases may, directly or indirectly, 
modulate AT. For example, reduced calcineurin (PP2) activity has been reported in animal models of HD 
(Gratuze et al., 2015), which lead to increased phosphorylation of tau. Interestingly, activation of calcineurin 
has been reported to enhance glucose-dependent insulin release from beta cells through a dephosphorylation 
of kinesin 1b (Donelan et al., 2002). 
 Kinases were also identified that regulated anterograde AT by phosphorylating kinesin-1 subunits of 
conventional kinesin. One example is the neuron-specific JNK isoform JNK3 which directly phosphorylates a 
highly conserved serine residue within kinesin-1 head domains, inhibiting the processive movement of 
conventional kinesin among microtubules (DeBerg et al., 2013; Morfini et al., 2009b). In addition, JNK3 also 
inhibited retrograde AT, but a molecular basis for this inhibitory effect has not been evaluated. Notably, the 
ubiquitously expressed JNK isoform JNK1 did not modulate AT, despite sharing a wide variety of JNK3 
substrates (Coffey, 2014). Similarly, the motor neuron-enriched p38α isoform (Ackerley et al., 2004; Carboni et 
al., 1998; Hu et al., 2003; Krieger et al., 2003) selectively inhibited anterograde AT by direct phosphorylation of 
selected kinesin-1 variants (Bosco et al., 2010; Morfini et al., 2013). In contrast the ubiquitously expressed p38 
isoforms p38γ and p38δ  had little or no effect on AT, while p38β inhibited both anterograde and retrograde AT. 
Identification of kinase isoform-specific functions can prove difficult, but the isolated axoplasm preparation has 
proven remarkably useful in the context of AT. Other kinases, including PKC isoforms (Morfini et al., 2007),  
CK1 and CK2 (Ikeda et al., 2011; Karki et al., 1997; Morfini et al., 2001; Pigino et al., 2009; Pigino et al., 2003; 
Solowska et al., 2008), have simillarly been reported to affect anterograde and/or retrograde AT in normal and 
pathological conditions. 
 Neuropathogenic proteins associated with familial forms of AONDs trigger AT alterations through 
activation of selected kinase pathways. As a number of kinases that affect AT were identified, an interesting 
pattern emerged: Many of the kinases identified as regulator of AT were also associated with one or more 
AONDs (Table 3). Relevant to AD pathogenesis, multiple independent reports documented increased GSK3 
activity in AD, as well as in various tauopathies (Cox et al., 2016; Crews and Masliah, 2010; Hernandez and 
Avila, 2008; Hernandez et al., 2010). Several different pathways may contribute to increased GSK3 activity in 
AD.  For example, GSK3β is activated by pathogenic forms of tau was shown to involve increased exposure of 
the PAD domain located in the extreme amino terminus of of tau, which in turn promoted PP1-dependent 
activation of GSK3 via PP1 (Kanaan et al., 2011; Lapointe et al., 2009), changes in AT would be expected in 
familial forms of AD and tauopathies. Further, increased GSK3 activation and concomitant deficits in AT were 
also found in mutant APP or presenilin 1-based cellular (Pigino et al., 2003) and mouse-based models 
(Lazarov et al., 2007). Highlighting the disease relevance of these findings, immunohistochemical analysis of 
post mortem AD and various tauopathy brain samples demonstrated increased PAD exposure as an early 
pathogenic event common to all these diseases (Cox et al., 2016).  
 Multiple independent reports document changes in AT in animal models of familial ALS (Borchelt et al., 
1998; Bosco et al., 2010; Breuer and Atkinson, 1988; Collard et al., 1995; De Vos et al., 2007; Gonzalez de 
Aguilar et al., 1999; Marinkovic et al., 2012; Morfini et al., 2013; Morotz et al., 2012; Sasaki and Iwata, 1996; 
Sasaki et al., 2005). In contrast to AD, pathogenesis in ALS has been linked to activation of P38 MAP kinases 
(Ackerley et al., 2004; Bendotti et al., 2004; Bendotti et al., 2005).  Activation of P38 MAP kinases is well 
documented in motor neurons in spinal cords of both sporadic and familial ALS (Bendotti et al., 2004; Bendotti 
et al., 2005; Bosco et al., 2010; Morfini et al., 2013). Again, changes in AT would be expected with activation of 
P38 MAP kinases in ALS (Bosco et al., 2010; Morfini et al., 2013).   
 Similarly, changes in PKCδ activity have been documented in Parkinson’s disease (Fan et al., 2014; 
Gordon et al., 2012; Gordon et al., 2016; Hanrott et al., 2008; Kaul et al., 2003) and increased PKCδ alters 
neuronal homeostasis by increasing retrograde AT and reducing anterograde AT (Morfini et al., 2007; Serulle 
et al., 2007).  Other examples include pathogenic mutant forms of spastin that cause hereditary spastic 
paraplegia and activate CK2, which inhibits both directions of AT (Solowska et al., 2008). Interestingly. Aβ 
oligomers associated with AD also activate CK2 and inhibit AT (Moreno et al., 2009; Pigino et al., 2009).  
Finally, pathogenic forms of huntingtin activate JNK3 which reduces both directions of AT (Morfini et al., 
2009b).  In each case, kinases that were identified as candidate regulators of AT were misregulated in one or 
more AOND.  As a result, one can expect changes in AT to be a feature of all these diseases and the available 
evidence validates this prediction.    
 
Concluding remarks. 
 For many years, the focus of research in AONDs was on preventing the loss of neurons. While progress 
was made in reducing neuronal cell death, there was little progress in affecting the progression of these 
diseases.  As evidence accumulates that preservation of neuronal connectivity and function is a key to 
addressing these devastating diseases, new therapeutic approaches will need to emerge.  Each AOND has a 
unique pathogenic progression, which means that a better understanding of the cell and molecular basis for 
specific AONDs is essential. The disruption in normal signaling pathways that is a common feature for many 
AONDs and the unique role of AT in maintaining neuronal connectivity and function may prove to be critical 
elements in developing these new therapeutic approaches.   
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 FIGURE LEGENDS 
 
Figure 1: A) Schematic depicting the subunit organization of conventional kinesin holoenzymes. The head 
domain of kinesin heavy chains (kinesin-1, KIF5s) contains protein motifs for microtubule binding and ATP 
hydrolysis. Joined by a short neck linker region, the long stalk features coiled-coil and hinge domains 
mediating homodimerization of kinesin-1s. In addition, kinesin-1s contain a globular tail domain unique to each 
kinesin-1 subunit variant. On the other hand, KLC subunits associate with the tail domain of conventional 
kinesin through heteromeric coiled coil domains. Both the carboxy terminus of KLCs and the tail domain of 
kinesin-1s play a role on the targeting of conventional kinesin variants to MBOs of unique protein composition. 
Cytoplasmic dynein has a more complex composition with multiple subunits. Unlike kinesin, there is only one 
gene for the cytoplasmic dynein heavy chain, but other subunits are more diverse. For example, there are two 
dynein intermediate chain genes and they may exhibit alternative splicing as well as post-translation 
modification. Thus, molecular motor featuring unique subunit combinations may associate with specific 
cargoes and may be subject to different signaling pathways for regulation.   B) Kinesin-1s and KLCs are 
organized as homodimers within the conventional kinesin holoenzyme (Deboer et al., 2008), potentially giving 
rise to six different conventional kinesin variants. In addition, KLC1 undergoes alternative splicing, potentially 
increasing the number and complexity of such variants. Similarly, cytoplasmic dynein may have either DIC1 or 
DIC2 as well as variability in other subunits and adapter proteins such as dynactin. The diversity in motors may 
allow interaction with different cargos (i.e. APP-containing vesicles preferentially interact with kinesin-1C 
(Szodorai et al., 2009) and signaling endosomes preferentially interact with cytoplasmic dynein containing 
DIC1 (Ha et al., 2008)) or may allow differential regulation (i.e. GSK3β preferentially modifies KLC2 (Morfini et 
al., 2002)).    
 
 
 
Figure 2: Three genes encoding kinesin-1 subunits are expressed in mammalian nervous system: kinesin-1A 
(KIF5A), kinesin-1B (KIF5B), and kinesin-1A (KIF5C). Antibodies that selectively recognize each one of these 
subunits (Deboer et al., 2008) reveal a unique distribution pattern for each subunit in different regions of the 
central nervous system, suggesting that different neurons display a unique complement of conventional kinesin 
heavy chain subunit variants: Br whole brain; ON optic nerve; SC spinal cord; SN sciatic nerve; OB olfactory 
bulb, CCX cerebral cortex; HIP hippocampus; and CB cerebellum. Note that kinesin-1A is widely expressed in 
nervous tissue, but that there are quantitative differences in different regions.  Kinesin-1B and kinesin-1C show 
more variability among brain regions. This and other observations imply cell type-specific specializations of 
axonal transport rarely recognized in the literature, which may contribute to the selective vulnerability of 
specific neuronal populations in different AONDs. 
 
 
 Figure 3: Axonal transport is disrupted by the presence of pathogenic forms of normal neuronal proteins, 
which lead to activation of specific kinase signaling pathways. For example, tau filaments activate a 
phosphatase PP1/GSK3β pathway (Kanaan et al., 2011), which preferentially phosphorylates conventional 
kinesin motors containing KLC2 (Morfini et al., 2002). This phosphorylation in turn leads to release of kinesin 
from the associated cargo vesicle.  Similarly, pathogenic forms of huntingtin activate a MAP kinase pathway 
leading to JNK3, which preferentially phosphorylates motors containing kinesin-1B and -1C subunits and 
inhibits their interaction with microtubules (Morfini et al., 2009b).  JNK3 also inhibits retrograde AT, but the 
specific cytoplasmic dynein subunit that is modified has not been identified.  
  
Table 1. Common Features of Adult-onset Neurodegenerative Diseases. 
 
COMMON FEATURES OF ADULT-ONSET NEURODEGENERATIVE DISEASES  
 
Etiological features  
- Both hereditary and idiopathic forms may exist with the same pathology. 
Clinical features 
- Asymptomatic during development and maturation of the nervous system. 
- Symptoms slowly progress for years after appearance of symptoms. 
Anatomical features 
- Projection neurons are affected primarily or exclusively affected. 
- Select subpopulations of projection neurons are affected. 
Cellular features 
- Misfolded proteins are a common element of both familial and idiopathic forms. 
- Altered synaptic function and neuritic pathology are early pathogenic events of the disease process.  
 
 Molecular features 
- Affected neurons exhibit alterations in kinase activity and aberrant pattern of protein phosphorylation. 
- Affected neurons exhibit deficits in axonal transport. 
 
 
 
 
 
 
Table 2.  Effects of selected kinases on AT  
Kinase Kinesin-1 Cytoplasmic Dynein 
GSK3β Inhibits No effect 
MAP kinase  
   -JNK1 
   -JNK2 
   -JNK3  
 
No effect 
Inhibits 
Inhibits 
 
No effect 
 
Inhibits 
MAP kinase 
   -P38α      
   -P38β 
   -P38γ 
   -P38δ 
 
Inhibits   
Inhibits 
Slight inhibition 
No effect 
 
No effect 
Inhibits 
Slight inhibition 
No effect 
MAP kinase kinase kinase 
   -ASK1     
   -Tak1      
   
 
Inhibits 
Inhibits 
 
 
No effect 
Inhibits 
 
CK1 Inhibits Inhibits 
CK2 Inhibits Inhibits 
PKCδ Inhibits  Activates 
 
 
 
  
Table 3.  Signaling Pathways aberrantly activated in selected AONDs. 
 
Disease Kinases implicated 
Both Familial and Sporadic forms  
   Alzheimer’s disease 
      - AD  
 
      - Aβ oligomers 
      - Tau filaments 
 
Cdk5, JNK, MARK, P38 MAPK, CK1, Fyn, Dyrk1A, 
GSK3 
CK2 
PP1/GSK3β pathway 
   Parkinson’s disease 
       - Synucleinopathies 
       - MPTP 
 
Abl, PINK1, LRRK2 
PKCδ, JNK 
   Amyotrophic Lateral Sclerosis 
       - SOD1  
P38 MAPK, TBK,  
ASK1,  
Familial forms only  
   Huntington’s disease JNK3, GSK3β, IKKB, ASK1, PKCδ   
   Hereditary Spastic Paraplegia 
     (Spastin, SPG4) 
CK2 
   Frontotemporal Dementia with  
     Parkinson’s 17 (FTDP17) 
PP1/GSK3β pathway 
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